Compare XMTR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XMTR | ERAS |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | 2021 | 2021 |
| Metric | XMTR | ERAS |
|---|---|---|
| Price | $89.86 | $18.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $58.60 | $14.25 |
| AVG Volume (30 Days) | 734.1K | ★ 3.2M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.95 | ★ 36.23 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $686,631,000.00 | N/A |
| Revenue This Year | $23.76 | N/A |
| Revenue Next Year | $18.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.87 | N/A |
| 52 Week Low | $35.86 | $1.33 |
| 52 Week High | $106.08 | $24.28 |
| Indicator | XMTR | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 53.18 |
| Support Level | $88.52 | $17.36 |
| Resistance Level | $98.55 | $19.96 |
| Average True Range (ATR) | 4.56 | 0.99 |
| MACD | 0.42 | -0.12 |
| Stochastic Oscillator | 56.12 | 67.76 |
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.